Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totaling 37,561 shares, a drop of 46.9% from the September 15th total of 70,672 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily volume of 18,763 shares, the short-interest ratio is presently 2.0 days.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exicure in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.
Read Our Latest Stock Report on Exicure
Exicure Stock Down 7.4%
XCUR opened at $1.12 on Friday. The company has a fifty day moving average price of $1.25 and a two-hundred day moving average price of $2.24. Exicure has a 52 week low of $0.94 and a 52 week high of $9.48.
Exicure (NASDAQ:XCUR – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($18.60) by $18.42.
Exicure Company Profile
Exicure, Inc is a biotechnology company that historically focused on developing nucleic acid-based medicines. Its research was built around Spherical Nucleic Acid (SNA) technology, a platform designed to package and deliver short strands of genetic material into cells to influence disease-related biological pathways.
The company’s development programs included investigational treatments for oncology, inflammatory diseases and genetic disorders. Its most prominent candidates included cavrotolimod, an immunotherapy designed to activate the toll-like receptor 9 pathway, and earlier dermatology-focused programs intended to address conditions such as psoriasis and related inflammatory diseases.
See Also
- Five stocks we like better than Exicure
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
